Oral Cavity (Mouth) Cancer - Pipeline Review, H2 2012


#135238

42pages

Global Markets Direct

$ 2000

In Stock


Oral Cavity (Mouth) Cancer Pipeline Review, H2 2012

Global Markets Directs, 'Oral Cavity (Mouth) Cancer Pipeline Review, H2 2012', provides an overview of the Oral Cavity (Mouth) Cancer therapeutic pipeline. This report provides information on the therapeutic development for Oral Cavity (Mouth) Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Oral Cavity (Mouth) Cancer. 'Oral Cavity (Mouth) Cancer Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Oral Cavity (Mouth) Cancer.
  • A review of the Oral Cavity (Mouth) Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. 
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Oral Cavity (Mouth) Cancer pipeline on the basis of route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Oral Cavity (Mouth) Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. 
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Oral Cavity (Mouth) Cancer pipeline depth and focus of Oral Cavity (Mouth) Cancer therapeutics. 
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Oral Cavity (Mouth) Cancer Therapeutic Products under Development, Key Players in Oral Cavity (Mouth) Cancer Therapeutics, Oral Cavity (Mouth) Cancer Pipeline Overview, Oral Cavity (Mouth) Cancer Pipeline, Oral Cavity (Mouth) Cancer Pipeline Assessment
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Oral Cavity (Mouth) Cancer Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Oral Cavity (Mouth) Cancer 7
Oral Cavity (Mouth) Cancer Therapeutics under Development by Companies 9
Oral Cavity (Mouth) Cancer Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Oral Cavity (Mouth) Cancer Therapeutics Products under Development by Companies 14
Oral Cavity (Mouth) Cancer Therapeutics Products under Investigation by Universities/Institutes 15
Companies Involved in Oral Cavity (Mouth) Cancer Therapeutics Development 16
CEL-SCI Corporation 16
Oral Cavity (Mouth) Cancer Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Combination Products 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Drug Profiles 23
Actos - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Fludarabine + Radiation Therapy - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Cisplatin + Paclitaxel + Radiation Therapy - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Taxotere + Cisplatin + 5-FU - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 27
Erbitux + Radiation Therapy - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Multikine + Cyclophosphamide + Indomethacin + Zinc - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 30
Multikine + Cisplatin - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 32
Erlotinib Hydrochloride + Linsitinib - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Erlotinib Hydrochloride - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Linsitinib - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Oral Cavity (Mouth) Cancer Therapeutics Discontinued Products 39
Oral Cavity (Mouth) Cancer Therapeutics - Dormant Products 40

Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 42
Disclaimer 42

Number of Products Under Development for Oral Cavity (Mouth) Cancer, H2 2012 7
Products under Development for Oral Cavity (Mouth) Cancer – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
CEL-SCI Corporation, H2 2012 16
Assessment by Monotherapy Products, H2 2012 17
Assessment by Combination Products, H2 2012 18
Assessment by Stage and Route of Administration, H2 2012 20
Assessment by Stage and Molecule Type, H2 2012 22
Oral Cavity (Mouth) Cancer Therapeutics – Discontinued Products 39
Oral Cavity (Mouth) Cancer Therapeutics – Dormant Products 40

Number of Products under Development for Oral Cavity (Mouth) Cancer, H2 2012 7
Products under Development for Oral Cavity (Mouth) Cancer - Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 17
Assessment by Combination Products, H2 2012 18
Assessment by Route of Administration, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 20
Assessment by Molecule Type, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 22